Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model

Chronic administration of L-DOPA, the first-line treatment of dystonic symptoms in childhood or in Parkinson’s disease, often leads to the development of abnormal involuntary movements (AIMs), which represent an important clinical problem. Although it is known that Riluzole attenuates L-DOPA-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagliaroli, Luca, Widomska, Joanna, Nespoli, Ester, Hildebrandt, Tobias, Barta, Csaba, Glennon, Jeffrey, Hengerer, Bastian, Poelmans, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647536/
https://www.ncbi.nlm.nih.gov/pubmed/30484112
http://dx.doi.org/10.1007/s12035-018-1433-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647536/
https://www.ncbi.nlm.nih.gov/pubmed/30484112
http://dx.doi.org/10.1007/s12035-018-1433-x

Ejemplares similares